SLE patients with high disease activity (Fig. 5F and G) showed expanded CD8 + HLA-DR + CD38 + (11.81 ± 1.076%, (N = 63) vs. 18.55 ± 3.281%, (N = 21), p = 0.0127; CD8 + HLA-DR + CD127 + 1.417 ± 0.1921%, (N = 42) vs. 3.24 ± 1.105%, (N = 10), p = 0.0076). This evidence concerns the gene CD38 and systemic lupus erythematosus.